Clinical trial Recruiting at 1 site Observational Ages 18 to 70

Using blood cell ratios and procalcitonin to predict outcomes for adults with sepsis in the ICU

Official title: Comparison Between Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.

Run by Ain Shams University · NCT07200817 · Data updated 2026-11-12

This project will test whether routine blood measures—neutrophil-to-lymphocyte-and-platelet ratio, procalcitonin, and total white blood cell count—can help predict outcomes for adults with sepsis in the intensive care unit.

More Intensive Care Unit trials

Quick facts

Study typeObservational
Ages18 Years to 70 Years
SexAll
Enrollment290 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedSeptember 20, 2024
Main results expectedMarch 19, 2026
Study endsMarch 19, 2026
Registry record updatedOctober 1, 2025
Trial IDNCT07200817 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18–70 who are admitted to the ICU with sepsis (per current sepsis definitions) and who do not have the listed exclusion conditions.

Probably not a fit

Patients who are pregnant, have active malignancy, are on immunosuppressive therapy, have hematologic disorders, major trauma or burns, Child-Pugh C cirrhosis, or are on hemodialysis are excluded and would not receive benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational ICU study that will collect routine laboratory values (neutrophil-to-lymphocyte-and-platelet ratio, procalcitonin, and total leukocyte count) from adult patients diagnosed with sepsis. Researchers will compare these biomarkers to patients' clinical outcomes such as mortality, organ failure, and length of ICU stay to see which markers best correlate with prognosis. The study excludes patients with pregnancy, malignancy, immunosuppression, hematologic disorders, major trauma or burns, advanced liver cirrhosis, or those on hemodialysis. No investigational treatments are given; data are drawn from standard care blood tests and clinical records.

Why it matters

Potential benefit: If successful, these low-cost, routinely available blood markers could help clinicians identify higher-risk sepsis patients earlier and better target monitoring and treatment.

How similar studies have gone: Previous studies have shown that procalcitonin and neutrophil/lymphocyte-based ratios often correlate with sepsis severity and mortality, but results have been variable and not yet definitive for routine prognostic use.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age from 18 to 70 years old.
* Both sexes.
* Septic patients (under the third international consensus definitions of sepsis and septic shock).

Exclusion Criteria:

* Pregnancy
* Malignancy
* On immunosuppressive therapy
* Hematological Disorders
* Major Trauma
* Major Burns
* Child-Pugh Class C Liver Cirrhosis
* On Hemodialysis

Where it's running

  • Ain Shams University
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.